In the evolving landscape of youth gender medicine, a growing number of medical professionals are raising alarms about the rapid adoption of gender-affirming care models. These models, which emphasize affirming a child’s self-identified gender through social transition, puberty blockers, and cross-sex hormones, have come under scrutiny for lacking robust evidence and potentially causing long-term harm. Yet, doctors who speak out often face severe professional repercussions, including suspension, legal battles, and reputational damage. The case of Dr. Jillian Spencer, a senior child psychiatrist at Queensland Children’s Hospital (QCH), exemplifies these challenges. Her story highlights the tension between medical ethics, institutional policies, and ideological pressures in Australia’s healthcare system—and raises questions about a troubling double standard in how dissent is treated compared to advocacy.
The Spark of Controversy: Questioning the Affirmation Model
Dr. Spencer’s ordeal began when she expressed concerns about what she perceived as an ideological culture at QCH. She altered her email signature to “woman – adult human female,” a move that hospital directors deemed potentially transphobic and ordered removed, citing concerns it might distress staff or patients. This was amid her broader criticisms of the hospital’s gender clinic, including excessive use of rainbow flags, lanyards, and mandatory pronoun inquiries, which she argued created an environment that pressured vulnerable children into gender transitions without adequate mental health assessments.
By April 2023, Dr. Spencer was suspended from clinical duties following a patient complaint of transphobia during her assessment of a 14-year-old on puberty blockers. Despite an unblemished career, she was restricted from patient contact but remained employed. Her public advocacy escalated the conflict: she spoke at women’s rights rallies, citing risks like infertility, loss of sexual function, and irreversible harm from hormone treatments. Drawing on emerging evidence from the UK’s Cass Review, she argued that the affirmation model lacked scientific backing and prioritized ideology over patient welfare.
Institutional Backlash and Legal Battles
The challenges Dr. Spencer faced underscore the broader hurdles for dissenting doctors in the gender-affirming care industry. Institutions like QCH enforced policies requiring clinicians to affirm transitions and support referrals without dissuasion, binding them under public service codes of conduct. When Dr. Spencer made public interest disclosures (PIDs) alleging unsafe practices, they were rejected by Queensland Health, which defended the model’s safety.
In 2024, a government review of the Queensland Children’s Gender Service (QCGS) affirmed its practices, but Dr. Spencer criticized it as biased, stacked with affirmation advocates, and dismissive of the Cass Review’s findings. This review, rather than addressing concerns, recommended expanding clinics – a move at odds with global shifts, such as the UK’s ban on puberty blockers for minors.
By 2025, under the new Crisafulli LNP government, Queensland paused new hormone therapies for under-18s pending an independent review by Professor Ruth Vine. Yet, Dr. Spencer’s situation worsened: she received a termination notice in September for alleged misconduct, including public statements that “disreputed” the hospital. This came before the Vine review’s completion, prompting accusations of subverting justice. Her legal team secured a stay on the termination, arguing breaches of political communication freedoms and human rights.
Dr. Spencer’s multiple Queensland Industrial Relations Commission (QIRC) cases seek whistleblower status, compensation, and reinstatement. She alleges discrimination based on her belief that sex cannot change and that child welfare should trump predetermined treatment paths. A pivotal Family Court judgment in June 2025, criticizing Australian guidelines as misleading and coercive, bolstered her position, yet institutional resistance persisted.
A Double Standard? Scrutiny for Dissent vs. Protection for Advocacy
Dr. Spencer’s case raises an uncomfortable question: why are doctors who question gender-affirming care subjected to disciplinary action while those promoting it face little scrutiny—even when their claims are challenged in court?
Consider the example of Associate Professor Michelle Telfer, a prominent clinician involved in developing the Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents, and long associated with the Royal Children’s Hospital Melbourne gender service.
In the Family Court case Re Devin (2025), Justice Andrew Strum raised serious concerns about expert evidence presented in support of gender-affirming treatment for a 12-year-old biologically male child. The judgment criticized the Royal Children’s Hospital for failing to formally diagnose gender dysphoria despite years of involvement, questioned the scientific basis of the guidelines, and described the affirmation approach as an “oddly binary” one that brooked no questioning—even for young children. Justice Strum found aspects of Telfer’s testimony (initially anonymized as “Associate Professor L”) to be misleading, overly ideological, and dismissive of counter-evidence like the Cass Review. He stripped the affirming parent of custody, blocked access to puberty blockers and hormones, and effectively halted medical transition.
Despite these judicial criticisms—including findings of misleading evidence and advocacy bias—there have been no comparable professional sanctions or investigations directed at Telfer or other clinicians who promoted those guidelines or gave similar expert testimony. A complaint lodged against Telfer with AHPRA (Australian Health Practitioner Regulation Agency) following the ruling was dismissed without action.
This contrast is striking:
- Doctors expressing caution, such as Dr. Spencer or psychiatrist Dr. Andrew Amos (who faced AHPRA-imposed restrictions in 2026 banning him from social media discussion of gender medicine and clinical patient contact over his evidence-based critiques), have endured suspensions, restrictions on practice, public complaints, and lengthy legal battles.
- Doctors advocating gender-affirming interventions, even when their claims are questioned in court or contradicted by emerging evidence (e.g., the Cass Review’s findings of weak evidence and risks), continue to practise without similar scrutiny.
The result is a clear asymmetry in professional risk. One side of the debate is heavily policed. The other is largely insulated.
Such an imbalance creates a chilling effect across the medical profession. Clinicians who harbour concerns about the evidence base for youth gender medicine may conclude that speaking openly could jeopardise their careers. In an environment where dissent carries significant professional risk, genuine scientific debate becomes increasingly difficult.
Broader Challenges in the Gender-Affirming Care Debate
Dr. Spencer’s case is not isolated. Doctors worldwide face similar risks when challenging the industry:
- Professional Isolation and Censorship: Speaking out invites complaints, investigations by bodies like AHPRA, and mandates to follow affirmation protocols, stifling clinical discretion.
- Legal and Financial Burdens: Lengthy court battles, as in Dr. Spencer’s four QIRC actions and Supreme Court review, drain resources and careers.
- Ideological Pressures: Hospitals prioritize “inclusivity” over evidence, enforcing pronoun use and gender recording that can compromise medical accuracy.
- Public and Political Backlash: While supported by groups like the National Association of Practising Psychiatrists (NAPP) and women’s rights advocates, critics label dissenters as transphobic, amplifying reputational harm.
- Evidence Gaps: Reviews like Cass and Vine highlight “limited” evidence for hormones, yet defenders cite outdated guidelines, creating a chilling effect on open debate.
These challenges reflect a system where whistleblowers risk everything to uphold the Hippocratic oath – “first, do no harm.” As Dr. Spencer noted, her loyalty is to patients, not institutions perpetuating unproven treatments.
A Call for Reform and Protection
The Vine Review’s December 2025 recommendation to extend Queensland’s hormone pause until at least 2031 aligns with international caution, vindicating skeptics like Dr. Spencer. Yet, her cases remain unresolved into 2026, with hearings pending. This saga calls for stronger protections for medical whistleblowers, independent oversight of gender clinics, and policies prioritizing evidence-based care over ideology.
For parents, patients, and professionals, Dr. Spencer’s resilience serves as a beacon. It’s time to foster environments where doctors can speak freely to safeguard children’s futures. If we silence voices like hers, we risk entrenching harm in the name of progress.